Evidence map›Paper›PMID 36206865›Full record

ArticleClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2023

Re: Remdesivir for the treatment of COVID-19 by Lee et al.

Alessia Beccacece, Tommaso Ascoli Bartoli, Emanuele Nicastri

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Alessia BeccaceceNational Institute for Infectious Diseases Lazzaro, Spallanzani Institute for Hospitalization and Care Scientific, Clinical, Division of Infectious Diseases, Italy. Electronic address: alessia.beccacece@inmi.it.
Tommaso Ascoli BartoliNational Institute for Infectious Diseases, Lazzaro Spallanzani Institute for Hospitalization and Care Scientific, Clinical Department, Italy.
Emanuele NicastriNational Institute for Infectious Diseases, Lazzaro Spallanzani Institute for Hospitalization and Care Scientific, Clinical Department, Italy; INMI "L. Spallanzani", Clinical Department, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Adenosine MonophosphateAlanineAntiviral AgentsCOVID-19 Drug TreatmentHumansSARS-CoV-2Adenosine MonophosphateAlanineAntiviral Agentsremdesivir

Identifiers

PMID36206865
PMCPMC9531359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.